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Abstract
Aims This study aimed to elucidate the risk for stroke and systemic embolism (SE) in patients with atrial fibrillation and heart
failure (HF) according to HF type.
Methods and results A total of 10 780 patients with atrial fibrillation were enrolled in a multicentre prospective registry and
divided according to HF type: no-HF, HF with preserved ejection fraction (EF) (HFpEF), HF with mid-range EF (HFmrEF), and HF
with reduced EF (HFrEF). Each group included 237 age-matched and sex-matched patients (age, 69.0 ± 10.3 years; men,
69.6%). The baseline characteristics, cumulative incidence, and hazard ratios for stroke/SE and major bleeding were compared
across the groups. Patients with HF accounted for 10.3% of the total population; HFpEF, HFmrEF, and HFrEF represented
43.7%, 23.6%, and 32.7% of the patients with HF, respectively. The CHA2DS2-VASc score was significantly higher in the HFpEF,
HFmrEF, and HFrEF groups than in the no-HF group. The annual stroke/SE incidence rates were 2.8%, 0.7%, 1.1%, and 0.9% in
the HFpEF, HFmrEF, HFrEF, and no-HF groups, respectively. The cumulative incidence of stroke/SE was significantly highest in
the HFpEF group at 22.8 ± 10.0 months (P = 0.020). The stroke/SE risk was higher in the HFpEF group than in the HFmrEF and
HFrEF groups (hazard ratio, 3.192; 95% confidence interval, 1.039–9.810; P = 0.043). E/e’ value was an independent risk factor
for stroke/SE. There were no significant differences in the incidence of major bleeding across the groups.
Conclusions The stroke/SE risk was the highest in the HFpEF group and comparable between the HFmrEF and HFrEF groups.
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Introduction
Atrial fibrillation (AF) is the most commonly observed type of
sustained arrhythmia. The risk for stroke and systemic
embolism (SE) increases according to the CHA2DS2-VASc score
in patients with AF.1 AF and heart failure (HF) often coexist and
share common risk factors. The prevalence of AF is increased
in patients with HF and vice versa.2,3 In addition, HF is among
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the risk factors for stroke and SE in patients with AF.1 Previ-
ously, HF was classified into HF with preserved ejection frac-
tion (HFpEF) and reduced ejection fraction (HFrEF), according
to the left ventricular (LV) ejection fraction (LVEF).4 Recently,
the guidelines for management of HF by the European Society
of Cardiology recommended a new category—HF with
mid-range ejection fraction (HFmrEF) for patients with HF
and an LVEF of 40–50%.5 There exists controversy surrounding
the risk for stroke and SE in patients with AF with HFpEF and
HFrEF. In addition, there is a lack of clarity on the risk for stroke
and SE in patients with AF and HFmrEF. Accordingly, the pres-
ent study aimed to elucidate the risk for stroke and SE in pa-
tients with AF and HF according to the HF type.
Methods
Study population
This was a prospective, multicentre cohort study. The study
design was approved by the institutional review board (num-
ber: 4-2016-0105) and registered at www.clinicaltrial.gov
(NCT02786095). The investigation conforms with the princi-
ples outlined in the Declaration of Helsinki. Patients aged
≥18 years with nonvalvular AF have been enrolled in a
multicentre, prospective, outpatient-based
registry—CODE-AF (COmparison study of Drugs for symptom
control and complication prEvention of AF) in 18 tertiary cen-
tres in the Republic of Korea since June 2016.6 Patients with
valvular AF (AF with moderate-to-severe mitral stenosis and a
mechanical valve), with transient AF due to reversible causes,
with a life expectancy <1 year, who were pregnant or
breastfeeding, and who required long-term anticoagulant
use for conditions other than AF were excluded.
Data collection
Detailed data on the patients’ medical history, including
their symptoms, past history, and medication history were ob-
tained. The results of laboratory tests [haemoglobin,
creatinine, and N-terminal pro-B-type natriuretic peptide
(NT-proBNP)], electrocardiography, and echocardiography
[LVEF, E/e’, left atrial (LA) diameter, and LA volume index (LV
volume/body surface area)] were collected. The CHA2DS2-
VASc score was used for the assessment of stroke and SE risk.
This score was defined as a sum of 1 for HF, 1 for hyperten-
sion, 2 for age ≥ 75 years, 1 for diabetes, 2 for prior stroke
or transient ischaemic attack (TIA), 1 for vascular disease, 1
for age 60–74 years, and 1 for female sex. The HAS-BLED score
was used for the assessment of bleeding risk. It was defined as
1 for uncontrolled hypertension, 1 for abnormal kidney or
liver function, 1 for prior stroke, 1 for bleeding tendency or
predisposition, 1 for labile international normalized ratio, 1
for age > 65 years, and 1 for usage of concomitant drugs pre-
disposing an individual to bleeding (antiplatelet agents or
nonsteroidal anti-inflammatory drugs) or alcohol intake (≥8
drinks/week). After enrolment, each patient was scheduled
to be followed up every 6 months, either through the outpa-
tient clinic or by a telephone interview. Data obtained from
June 2016 to January 2020 were analysed in the present study.
Data analyses
The patients were divided into four groups according to their
HF type: no-HF, HFpEF, HFmrEF, and HFrEF. HF was defined as
a condition in which the heart is unable to pump enough
blood to meet the body’s oxygen requirement. HFpEF was
defined as the presence of symptoms or signs related to HF,
an LVEF ≥ 50%, elevated level of natriuretic peptides
(NT-proBNP > 125 pg/mL), and relevant structural heart
disease (LV hypertrophy or LA enlargement) or diastolic dys-
function. HFmrEF was defined as the presence of symptoms
or signs related to HF, LVEF of 40–49%, an elevated level of na-
triuretic peptides (NT-proBNP > 125 pg/mL), and relevant
structural heart disease (LV hypertrophy or LA enlargement)
or diastolic dysfunction. HFrEF was defined as the presence
of symptoms or signs related to HF and an LVEF< 40%.5 After
the patients with intermediate or high risk (CHA2DS2-VASc
score ≥ 1 in men and CHA2DS2-VASc score ≥ 2 in women)
who did not take oral anticoagulant were excluded,
age-matched and sex-matched patients were included in the
four groups. The endpoints were stroke/SE and major bleed-
ing. Stroke/SE included stroke, TIA, and embolic events in
any area or organ. Diagnosis of stroke and TIA was made
based on brain magnetic resonance imaging by neurologists.
Diagnosis of embolism of the other area or organ was made
based on computed tomography. Major bleeding was defined
as fatal bleeding, symptomatic bleeding in a critical area or
organ, and bleeding causing a decrease in the haemoglobin
level by 2 g/dL or more or leading to the requirement of
transfusion of two or more units of red blood cells, based
on International Society on Thrombosis and Haemostasis
criteria.7 Data on the baseline characteristics, cumulative inci-
dence of stroke/SE and major bleeding, and risk for stroke/SE
and major bleeding were compared across the four groups.
Echocardiographic parameters (LVEF, E/e’, LA diameter, and
LA volume index) were analysed for the elucidation of the in-
dependent risk factors for stroke/SE in the patients with HF.
Statistical analyses
Continuous data are expressed as mean ± standard deviation,
whereas categorical data are presented as numbers (%). Data
matching was conducted for the adjustment of differences in
the patients’ age and sex using a multi-group propensity
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score matching method.8 The patients underwent 1:1:1:1
matching according to age group (by 5 years) and sex and
were then included in each group. We compared the baseline
characteristics of the patients across the four groups using a
one-way analysis of variance with Bonferroni’s test for post
hoc analyses of the continuous data and a χ2 test for the cat-
egorical data. The Kaplan–Meier method was used to analyse
the cumulative incidence of stroke/SE and major bleeding
across the four groups. Cox regression analyses were used
to compare the hazard ratios for stroke/SE and major bleed-
ing across the four groups and elucidate the independent
echocardiographic risk factors for stroke/SE. The results of
the Cox regression analyses are expressed as hazard ratios
and 95% confidence intervals. A P-value < 0.05 for a two-
sided test was considered statistically significant. Data were
analysed using Statistical Package for the Social Sciences Ver-
sion 25.0 (IBM Corporation, Armonk, NY, USA) and R software




A total of 10 780 patients (age, 66.8 ± 11.1 years; male,
64.7%) with nonvalvular AF were included in this registry.
Table 1 shows the baseline characteristics of the total popu-
lation of the patients in each group. Overall, 10.3% of the pa-
tients had HF. Those with HFpEF, HFmrEF, and HFrEF
comprised 43.7%, 23.6%, and 32.7% of the total HF popula-
tion, respectively.
A total of 948 age-matched and sex-matched patients (age,
69.0 ± 10.3 years; men, 69.6%) were included in the analyses;
237 were assigned to each group. Table 2 shows the baseline
characteristics of the age-matched and sex-matched patients
in each group. The matching variables (age and sex) were well
balanced across the groups. Paroxysmal AF was significantly
more frequently reported in the no-HF group than in the
HFpEF, HFmrEF, and HFrEF groups. The CHA2DS2-VASc score
was significantly higher in the HFpEF, HFmrEF, and HFrEF
groups than in the no-HF group. There were no significant dif-
ferences in the CHA2DS2-VASc score across the HFpEF,
HFmrEF, and HFrEF groups. There were no significant differ-
ences in the HAS-BLED score across the four groups. Vascular
disease and prior myocardial infarction were significantly
more frequently reported in the HFmrEF and HFrEF groups
than in the no-HF and HFpEF groups. There were no signifi-
cant differences in the frequency of hypertension, uncon-
trolled (systolic blood pressure ≥ 140 mmHg or diastolic
blood pressure ≥ 90 mmHg even with antihypertensive
agents) hypertension, diabetes, stroke history, chronic kidney
disease, end-stage renal disease, and creatinine level across
the four groups. The NT-proBNP level was significantly higher
in the HF groups than in the no-HF group, while the E/e’ value
was significantly higher in the HFrEF group than in the no-HF,
HFpEF, and HFmrEF groups. The LA volume index was
significantly higher in the HFpEF and HFrEF groups than in
the no-HF group. There were no significant differences in
the LA volume index across the HFpEF, HFmrEF, and
HFrEF groups. There were no significant differences in the
administration rates of antiplatelet agents across the
four groups. Usage of antiarrhythmic drugs was significantly
lower in the HFrEF group than in the other groups. Usage
of angiotensin-converting enzyme inhibitors or angiotensin
receptor blockers and beta-blockers was significantly
higher in the HF groups than in the no-HF group. Usage of
mineralocorticoid receptor antagonist was significantly
higher in the HFmrEF and HFrEF groups than in the no-HF
Table 1 Baseline characteristics of the total population
No-HF (n = 9666) HFpEF (n = 487) HFmrEF (n = 263) HFrEF (n = 364) P-value
Age (years) 66.6 ± 11.0a 70.2 ± 11.1b 68.6 ± 11.2b,c 66.9 ± 11.6a,c <0.001
Male 6274 (64.9)a 260 (53.4)b 178 (67.7)c 260 (71.4)d <0.001
Paroxysmal AF 6417 (66.4)a 222 (45.6)b 106 (40.3)c 185 (50.8)d <0.001
CHA2DS2-VASc score 2.5 ± 1.6a 4.0 ± 1.7b 3.8 ± 1.8b 3.7 ± 1.7b <0.001
Hypertension 6286 (65.0)a 358 (73.5)b 159 (60.5)c 237 (65.1)d 0.001
Diabetes 2363 (24.4)a 127 (26.1)a,b 76 (28.9)b,c 114 (31.3)c 0.009
Stroke history 1473 (15.2)a 81 (16.6)a,b 53 (20.2)b,c 80 (22.0)c 0.001
Vascular disease 548 (5.7)a 38 (7.8)b 35 (13.3)c 55 (15.1)c <0.001
HAS-BLED score 1.8 ± 1.1a 2.2 ± 1.2b 1.9 ± 1.2a,c 2.0 ± 1.2c <0.001
LVEF (%) 62.5 ± 7.0a 60.0 ± 6.0b 43.9 ± 2.6c 31.4 ± 6.1d <0.001
LA diameter (mm) 43.2 ± 8.1a 47.1 ± 8.4b 46.8 ± 8.2b 47.7 ± 9.3b <0.001
LA volume index (mL/m2) 26.7 ± 15.6a 36.6 ± 24.3b 34.3 ± 17.7b 37.0 ± 19.6b <0.001
OAC 7616 (78.8)a 436 (89.5)b 246 (93.5)c 334 (91.8)c <0.001
AF, atrial fibrillation; HF, heart failure; HFmrEF, heart failure with mid-range ejection fraction; HFpEF, heart failure with preserved ejection
fraction; HFrEF, heart failure with reduced ejection fraction; LA, left atrium; LVEF, left ventricular ejection fraction; OAC, oral
anticoagulant.
Values are presented as mean ± standard deviation for continuous variables or as number (%) for categorical variables.
The same subscript letters indicate non-significant differences and the different subscript letters indicate significant differences across the
groups based on Bonferroni multiple comparison tests.
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and HFpEF groups. The patients were followed up for
22.8 ± 10.0 months.
Stroke/systemic embolism and major bleeding
The annual stroke/SE incidence was 2.8% in the HFpEF group,
0.7% in the HFmrEF group, 1.1% in the HFrEF group, and 0.9%
in the no-HF group. The cumulative incidence of stroke/SE
was significantly higher in the HFpEF group than in the no-
HF (P = 0.025) and HFmrEF (P = 0.015) groups (Figure 1).
There were no significant differences in the cumulative inci-
dence of stroke/SE across the HFpEF and HFrEF groups
(P = 0.068). There were no significant differences in the cu-
mulative incidence of stroke/SE across the HFmrEF, HFrEF,
and no-HF groups. The risk for stroke/SE was significantly
higher in the HFpEF group than in the no-HF group, after ad-
justment for the hypertension, diabetes, stroke/TIA history,
and vascular disease (Table 3). There were no significant dif-
ferences in the risk for stroke/SE between the HFmrEF and
no-HF groups and between the HFrEF and no-HF groups.
Stroke occurred in eight, two, three, and four patients in
the HFpEF, HFmrEF, HFrEF, and no-HF groups, respectively.
TIA occurred in three and one patient in the HFpEF and HFrEF
groups. Renal infarction occurred in two, one, and one pa-
tient in the HFpEF, HFmrEF, and HFrEF groups, respectively.
The annual major bleeding incidence was 0.7% in the
HFpEF group, 0% in the HFmrEF group, 0.2% in the HFrEF
group, and 0.2% in the no-HF group. There were no signifi-
cant differences in the cumulative incidence of major bleed-
ing across the four groups (Figure 1). The risk for major
bleeding was not increased in the HFpEF, HFmrEF, and HFrEF
groups, compared with that in the no-HF group, after adjust-
ment for the HAS-BLED score (Table 4).
Echocardiographic parameters as risk factors for
stroke/systemic embolism in patients with heart
failure
Elevated E/e’ value was an independent risk factor for stroke/
SE after adjustment for hypertension, diabetes, stroke/TIA
history, vascular disease, and HF type (Table 5). However,
Table 2 Baseline characteristics of the age-matched and sex-matched patients
No-HF (n = 237) HFpEF (n = 237) HFmrEF (n = 237) HFrEF (n = 237) P-value
Age (years) 69.0 ± 10.3 69.0 ± 10.2 69.0 ± 10.4 69.1 ± 10.4 >0.999
Male 69.6 69.6 69.6 69.6 1.000
BMI (kg/m2) 24.7 ± 3.3a,b 24.9 ± 3.6a 24.4 ± 3.3a,b 24.1 ± 3.2b 0.024
Paroxysmal AF 62.9a 45.1b 38.1b 46.8b <0.001
CHA2DS2-VASc score 2.7 ± 1.6a 3.7 ± 1.7b 3.8 ± 1.8b 3.9 ± 1.7b <0.001
Hypertension 65.8 69.6 59.1 65.8 0.110
Diabetes 27.0 26.6 28.7 31.6 0.605
Stroke history 15.6 19.0 20.7 23.2 0.206
Vascular disease 6.3a 6.8a 11.8b 13.5b 0.014
HAS-BLED score 1.9 ± 1.0 2.1 ± 1.2 1.9 ± 1.2 2.0 ± 1.2 0.053
Uncontrolled hypertension 17.7 16.9 12.7 19.0 0.276
Myocardial infarction 1.7a 3.4a 6.8b 9.3b 0.001
Chronic kidney disease 8.5 13.5 13.5 14.9 0.175
End-stage renal disease 0.4 1.7 1.7 1.7 0.543
Haemoglobin (g/dL) 13.9 ± 1.8 13.6 ± 2.5 13.8 ± 2.0 13.8 ± 2.1 0.434
Creatinine (mg/dL) 1.0 ± 0.8 1.1 ± 0.6 1.1 ± 0.8 1.1 ± 1.0 0.290
NT-proBNP (pg/mL) 16.0 ± 39.5a 856.9 ± 673.1b 2519.6 ± 2534.1b,c 4046.2 ± 3971.6c <0.001
LVEF (%) 62.3 ± 6.9a 59.7 ± 5.6b 43.9 ± 2.6c 31.6 ± 6.3d <0.001
E/e’ 11.9 ± 6.0a 12.4 ± 6.1a 12.9 ± 6.2a 16.2 ± 8.5b <0.001
LA diameter (mm) 43.7 ± 8.1a 47.0 ± 8.3b 46.7 ± 8.1b 48.1 ± 9.9b <0.001
LA volume index (mL/m2) 48.6 ± 25.3a 63.2 ± 46.0b 58.3 ± 27.2a,b 65.5 ± 32.3b <0.001
Antiplatelet agent 21.5 15.6 16.0 17.3 0.312
OAC + antiplatelet agent 21.5 15.6 16.0 17.3 0.312
Antiarrhythmic drugs 42.2a 46.4a 37.1a 29.1b 0.001
ACE-I or ARB 37.1a 60.8b 63.3b,c 70.0c <0.001
Beta-blockers 46.0a 60.3b 66.7b 75.1c <0.001
MR antagonist 1.3a 3.4a 6.3b 7.6b 0.004
FU duration (months) 23.5 ± 9.5 23.5 ± 10.3 21.9 ± 9.8 22.3 ± 10.1 0.214
ACE-I, angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin receptor blocker; BMI, body mass index; FU, fol-
low-up; HF, heart failure; HFmrEF, heart failure with mid-range ejection fraction; HFpEF, heart failure with preserved ejection fraction;
HFrEF, heart failure with reduced ejection fraction; LA, left atrium; LVEF, left ventricular ejection fraction; MR, mineralocorticoid receptor;
NT-proBNP, N-terminal pro-B-type natriuretic peptide; OAC, oral anticoagulant.
Values are presented as mean ± standard deviation for continuous variables or as number (%) for categorical variables.
The same subscript letters indicate non-significant differences and the different subscript letters indicate significant differences across the
groups based on Bonferroni multiple comparison tests.
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Table 3 Incidence and risk of stroke/systemic embolism according to heart failure type
Group Annual incidence
Univariable Multivariable
Hazard ratio (95% CI) P-value Hazard ratio (95% CI)a P-value
No-HF 0.9 1.000 (reference) 1.000 (reference)
HFpEF 2.8 3.348 (1.091–10.273) 0.035 3.192 (1.039–9.810) 0.043
HFmrEF 0.7 0.806 (0.180–3.605) 0.778 0.806 (0.179–3.616) 0.778
HFrEF 1.1 1.322 (0.355–4.923) 0.678 1.261 (0.336–4.724) 0.731
CI, confidence interval; HF, heart failure; HFmrEF, heart failure with mid-range ejection fraction; HFpEF, heart failure with preserved ejec-
tion fraction; HFrEF, heart failure with reduced ejection fraction.
aHazard ratio and 95% confidence interval that were compared with no-HF and adjusted for hypertension, diabetes, stroke/transient isch-
aemic attack history, and vascular disease.
Figure 1 Cumulative incidence of stroke/systemic embolism (A) and major bleeding (B) according to heart failure type. HF, heart failure; HFmrEF, heart
failure with mid-range ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; SE,
systemic embolism.
Table 4 Risk for major bleeding according to heart failure type
Group Annual incidence
Univariable Multivariable
Hazard ratio (95% CI) P-value Hazard ratio (95% CI)a P-value
No-HF 0.2 1.000 (reference) 1.000 (reference)
HFpEF 0.7 4.198 (0.469–37.569) 0.200 4.118 (0.459–36.954) 0.206
HFmrEF 0 — — — —
HFrEF 0.2 1.071 (0.067–17.130) 0.961 1.224 (0.076–19.621) 0.887
CI, confidence interval; HF, heart failure; HFmrEF, heart failure with mid-range ejection fraction; HFpEF, heart failure with preserved ejec-
tion fraction; HFrEF, heart failure with reduced ejection fraction.
aHazard ratio and 95% confidence interval that were compared with no-HF and adjusted for uncontrolled hypertension, abnormal liver/
kidney function, stroke history, bleeding tendency, labile international normalized ratio, and concomitant drugs predisposing to bleeding
or alcohol intake.
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The main findings of the present study are as follows: (i) the
cumulative incidence and risk of stroke/SE were significantly
higher in the HFpEF group than in the other HF groups; (ii)
the cumulative incidence and risk of stroke/SE were compa-
rable between the HFmrEF and HFrEF groups; (iii) there were
no significant differences in terms of major bleeding across
the groups; and (iv) high E/e’ value was an independent risk
factor for stroke/SE.
Stroke/systemic embolism in patients with atrial
fibrillation and heart failure according to heart
failure type
The results of previous studies pertaining to the risk for
stroke/SE in patients with AF and HF, according to HF type,
are inconsistent. In these previous studies, HF was grouped
into HFpEF and HFrEF. Moreover, the cut-off LVEF values used
for the classification of patients into the HFpEF and HFrEF
groups differed across the studies, between 40% and 50%;
this indicates that HFmrEF was classified as HFpEF at a
cut-off of 40% whereas HFmrEF was classified as HFrEF at a
cut-off of 50%. The subgroup analyses of the ARISTOTLE trial
demonstrated that the risk for stroke/SE in patients with an
LVEF ≤ 40% was comparable with that observed in patients
with HF and an LVEF > 40%.9 The ORBIT-AF study revealed
that the risk for stroke was similar between patients with
HFpEF and HFrEF (LVEF ≤ 40%).10 Medical insurance data ob-
tained from the USA showed that the risk for ischaemic
stroke was comparable between people with HFpEF and
HFrEF, based on the International Classification of Disease,
9th revision code.11 Retrospective single-centre data from
Japan demonstrated the absence of significant differences
in the SE rate between patients with HFpEF and HFrEF
(LVEF < 50%).12 In contrast, Korean prospective AF registry
data (CODE-AF study) revealed that the risk for stroke/SE
was higher in patients with HFpEF than in patients with HFrEF
(LVEF < 50%).13
In only few studies focusing on the risk for stroke/SE in
patients with AF and HF, HF was grouped into HFpEF,
HFmrEF, and HFrEF. Consistent with the present study, the
Swedish HF registry showed that the composite incidence
of stroke or TIA or death was higher in patients with HFpEF
and lower in HFmrEF than in the other HF types.14 In con-
trast, the European AF registry (PREFER in AF-HF substudy)
revealed that the risk of thromboembolic events was the
highest in the HFrEF group, followed by the HFmrEF and
HFpEF groups.15
Epidemiological studies have reported a close relationship
between AF and HFpEF.16 Although it is not clear why the risk
for stroke/SE was the highest in the HFpEF group in the pres-
ent study, the following explanation may be plausible. High
E/e’ value was identified as an independent risk factor for
stroke/SE. The risk for stroke/SE was not associated with
LVEF. These findings suggest that LV diastolic dysfunction
contributes to the risk for stroke/SE rather than LV systolic
dysfunction in patients with AF and HF. LV diastolic dysfunc-
tion may contribute to stroke/SE via the following mecha-
nism: blood flow from the LA to LV is hindered under
conditions of LV diastolic dysfunction. Impairment of the
blood flow to the LV results in blood stasis in the LA, which
leads to predisposition to thrombus formation, subsequently
resulting in an increase in the risk for stroke/SE. Therefore,
the use of anticoagulation therapy is imperative in patients
with AF and HFpEF or LV diastolic dysfunction. However, this
explanation is not sufficient, as patients with HFrEF, HFmrEF,
and HFpEF also have diastolic dysfunction. High prevalence of
hypertension and high warfarin administration rate in the
HFpEF group might partly contribute to the risk for stroke/SE.
Major bleeding in patients with atrial fibrillation
and heart failure
The findings of previous studies and the present study are
consistent as the risk for major bleeding in patients with AF
Table 5 Risk associated with echocardiographic parameters for stroke/systemic embolism
Univariable Multivariable
Hazard ratio (95% CI) P-value Hazard ratio (95% CI)a P-value
LVEF (%) 1.006 (0.968–1.045) 0.764 1.003 (0.967–1.041) 0.874
E/e’ 1.056 (1.017–1.095) 0.004 1.070 (1.022–1.120) 0.004
LA diameter 1.078 (1.003–1.158) 0.040 1.064 (0.985–1.150) 0.114
LA volume index 0.995 (0.974–1.016) 0.614 0.998 (0.977–1.020) 0.856
CI, confidence interval; LA, left atrium; LVEF, left ventricular ejection fraction.
aHazard ratio and 95% confidence interval that were adjusted for hypertension, diabetes, stroke/transient ischaemic attack history, vascu-
lar disease, and heart failure type.
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and HF was comparable across the HF types. The subgroup
analyses of the ARISTOTLE trial showed that the risk for major
bleeding was not different between patients with an
LVEF ≤ 40% and patients with HF and an LVEF > 40%.9
Apixaban use reduced the risk for bleeding, compared with
warfarin.9 The medical insurance data from the USA revealed
that the risk for bleeding was comparable between patients
with HFpEF and HFrEF.11 The CODE-AF study data demon-
strated that the risk for major bleeding was not different be-
tween HFpEF and HFrEF (LVEF < 50%).13 The European AF
registry (PREFER in AF-HF substudy) revealed that the level
of bleeding risk was not different across the HFrEF, HFmrEF,
and HFpEF groups.15 In summary, these findings suggest that
the risk for major bleeding is not associated with HF type.
Limitations
First, follow-up echocardiography data were not available.
Therefore, reversible LV dysfunction was not detected. Sec-
ond, the follow-up duration was relatively short. Third, the
types of oral anticoagulants [warfarin and non-vitamin K an-
tagonist oral anticoagulants (NOACs)] used were not consis-
tent in the study population. Generally, the bleeding risk
associated with warfarin is higher than that related to NOAC
use. Therefore, the proportion of people who were taking
warfarin and NOACs may have affected the incidence of ma-
jor bleeding. Fourth, data on international normalized ratio in
the patients who were taking warfarin were not available.
Fifth, data on the indications of antiplatelet agents in the pa-
tients who were taking antiplatelet agents were not avail-
able. Sixth, data on dosage of the drugs that the patients
were taking during the study period were not available. Sev-
enth, data on stroke subtypes were not available.
Conclusions
In patients with AF and HF, the risk for stroke/SE was the
highest in association with HFpEF among the three HF types.
The risk for stroke/SE was comparable between HFmrEF and
HFrEF. LV diastolic dysfunction may contribute to the risk for
stroke/SE.
Acknowledgement




This work was supported by the Basic Science Research Pro-
gram through the National Research Foundation of Korea
(NRF), which is funded by the Ministry of Science, ICT, and Fu-
ture Planning (NRF-2012R1A2A2A02045367, 2010-0021993),
and grants from the Korean Healthcare Technology R&D Pro-
ject, which is funded by the Ministry of Health and Welfare
(HI12C1552, HI16C0058, and HI15C1200).
References
1. Lip GY, Nieuwlaat R, Pisters R, Lane DA,
Crijns HJ. Refining clinical risk stratifica-
tion for predicting stroke and thrombo-
embolism in atrial fibrillation using a
novel risk factor-based approach: the
euro heart survey on atrial fibrillation.
Chest 2010; 137: 263–272.
2. Maisel WH, Stevenson LW. Atrial fibril-
lation in heart failure: epidemiology,
pathophysiology, and rationale for ther-
apy. Am J Cardiol 2003; 91: 2d–8d.
3. Odutayo A, Wong CX, Hsiao AJ,
Hopewell S, Altman DG, Emdin CA.
Atrial fibrillation and risks of cardiovas-
cular disease, renal disease, and death:
systematic review and meta-analysis.
BMJ 2016; 354: i4482.
4. Yancy CW, Jessup M, Bozkurt B, Butler
J, Casey DE Jr, Drazner MH, Fonarow
GC, Geraci SA, Horwich T, Januzzi JL,
Johnson MR, Kasper EK, Levy WC,
Masoudi FA, McBride PE, McMurray JJ,
Mitchell JE, Peterson PN, Riegel B, Sam
F, Stevenson LW, Tang WH, Tsai EJ,
Wilkoff BL. 2013 ACCF/AHA guideline
for the management of heart failure: a
report of the American College of Cardi-
ology Foundation/American Heart Asso-
ciation Task Force on Practice
Guidelines. J Am Coll Cardiol 2013; 62:
e147–e239.
5. Ponikowski P, Voors AA, Anker SD,
Bueno H, Cleland JGF, Coats AJS, Falk
V, González-Juanatey JR, Harjola VP,
Jankowska EA, Jessup M, Linde C,
Nihoyannopoulos P, Parissis JT, Pieske
B, Riley JP, Rosano GMC, Ruilope LM,
Ruschitzka F, Rutten FH, van der Meer
P. 2016 ESC Guidelines for the diagnosis
and treatment of acute and chronic
heart failure: the Task Force for the di-
agnosis and treatment of acute and
chronic heart failure of the European
Society of Cardiology (ESC) Developed
with the special contribution of the
Heart Failure Association (HFA) of the
ESC. Eur Heart J 2016; 37: 2129–2200.
6. Kim H, Kim TH, Cha MJ, Lee JM, Park J,
Park JK, Kang KW, Shim J, Uhm JS, Kim
J, Park HW, Choi EK, Kim JB, Kim C, Lee
YS, Joung B. A prospective survey of
atrial fibrillation management for
real-world guideline adherence: COm-
parison study of Drugs for symptom con-
trol and complication prEvention of
Atrial Fibrillation (CODE-AF) registry.
Korean Circ J 2017; 47: 877–887.
7. Schulman S, Kearon C. Definition of ma-
jor bleeding in clinical investigations of
antihemostatic medicinal products in
1588 J.-S. Uhm et al.
ESC Heart Failure 2021; 8: 1582–1589
DOI: 10.1002/ehf2.13264
non-surgical patients. J Thromb Haemost
2005; 3: 692–694.
8. McCaffrey DF, Griffin BA, Almirall D,
Slaughter ME, Ramchand R, Burgette
LF. A tutorial on propensity score esti-
mation for multiple treatments using
generalized boosted models. Stat Med
2013; 32: 3388–3414.
9. McMurray JJ, Ezekowitz JA, Lewis BS,
Gersh BJ, van Diepen S, Amerena J,
Bartunek J, Commerford P, Oh BH,
Harjola VP, Al-Khatib SM, Hanna M,
Alexander JH, Lopes RD, Wojdyla DM,
Wallentin L, Granger CB. Left ventricu-
lar systolic dysfunction, heart failure,
and the risk of stroke and systemic em-
bolism in patients with atrial fibrillation:
insights from the ARISTOTLE trial. Circ
Heart Fail 2013; 6: 451–460.
10. Cherian TS, Shrader P, Fonarow GC,
Allen LA, Piccini JP, Peterson ED,
Thomas L, Kowey PR, Gersh BJ,
Mahaffey KW. Effect of atrial fibrillation
on mortality, stroke risk, and quality-of-
life scores in patients with heart failure
(from the Outcomes Registry for Better
Informed Treatment of Atrial Fibrillation
[ORBIT-AF]). Am J Cardiol 2017; 119:
1763–1769.
11. Mentias A, Briasoulis A, Shantha G,
Alvarez P, Vaughan-Sarrazin M. Impact
of heart failure type on thromboembolic
and bleeding risk in patients with atrial
fibrillation on oral anticoagulation. Am
J Cardiol 2019; 123: 1649–1653.
12. Sobue Y, Watanabe E, Lip GYH,
Koshikawa M, Ichikawa T, Kawai M,
Harada M, Inamasu J, Ozaki Y. Throm-
boembolisms in atrial fibrillation and
heart failure patients with a preserved
ejection fraction (HFpEF) compared to
those with a reduced ejection fraction
(HFrEF). Heart Vessels 2018; 33:
403–412.
13. Chung S, Kim TH, Uhm JS, Cha MJ, Lee
JM, Park J, Park JK, Kang KW, Kim J,
Park HW, Choi EK, Kim JB, Kim CS, Lee
YS, Shim J, Joung B. Stroke and sys-
temic embolism and other adverse out-
comes of heart failure with preserved
and reduced ejection fraction in patients
with atrial fibrillation (from the
COmparison study of Drugs for symp-
tom control and complication prEven-
tion of Atrial Fibrillation [CODE-AF]).
Am J Cardiol 2020; 125: 68–75.
14. Sartipy U, Dahlström U, Fu M, Lund LH.
Atrial fibrillation in heart failure with
preserved, mid-range, and reduced ejec-
tion fraction. JACC Heart Fail 2017; 5:
565–574.
15. Siller-Matula JM, Pecen L, Patti G,
Lucerna M, Kirchhof P, Lesiak M, Huber
K, Verheugt FWA, Lang IM, Renda G,
Schnabel RB, Wachter R, Kotecha D,
Sellal JM, Rohla M, Ricci F, De Caterina
R. Heart failure subtypes and thrombo-
embolic risk in patients with atrial fibril-
lation: the PREFER in AF-HF substudy.
Int J Cardiol 2018; 265: 141–147.
16. Zakeri R, Chamberlain AM, Roger VL,
Redfield MM. Temporal relationship
and prognostic significance of atrial fi-
brillation in heart failure patients with
preserved ejection fraction: a
community-based study. Circulation
2013; 128: 1085–1093.
Stroke risk in AF and HF 1589
ESC Heart Failure 2021; 8: 1582–1589
DOI: 10.1002/ehf2.13264
